Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | RBBP5 | Q15291 | 3/20 | 0.50 |
| ▸ | DPY30 | Q9C005 | 3/20 | 0.50 |
| ▸ | ASH2L | Q9UBL3 | 3/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | NNMT | P40261 | 4/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TRDMT1 | O14717 | 2/20 | 0.45 |
| ▸ | GNMT | Q14749 | 1/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18590706 | 1.00 | WDR5 (0.50) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL18592643 | 1.00 | WDR5 (0.50) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL14703563 | 0.95 | SMYD3 (0.51) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL803938 | 0.95 | SMYD3 (0.51) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL18592642 | 0.95 | SMYD3 (0.51) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15386705 | 0.90 | WDR5 (0.48) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL22821777 | 0.90 | WDR5 (0.48) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL803942 | 0.89 | EZH2 (0.48) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL14703564 | 0.89 | EZH2 (0.48) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120640 | 0.86 | TRDMT1 (0.44) | WDR5KMT2ARBBP5DPY30ASH2L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333217-B2 | Inhibitors of human EZH2, and methods of use thereof | Epizyme, Inc. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334527-B2 | Inhibitors of human EZH2, and methods of use thereof | Epizyme, Inc. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9175331-B2 | Inhibitors of human EZH2, and methods of use thereof | Epizyme, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150141362-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | Epizyme, Inc. | 2015-05-21 | — | — | US | disclosed |
| US-8895245-B2 | Inhibitors of human EZH2 and methods of use thereof | Epizyme, Inc. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140275081-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8691507-B2 | Inhibitors of human EZH2 and methods of use thereof | Epizyme, Inc. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130303555-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | Epizyme, Inc. | 2013-11-14 | — | — | US | disclosed |
| US-20130040906-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | Epizyme, Inc. | 2013-02-14 | — | — | US | disclosed |
| US-20120071418-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | Epizyme, Inc. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303555-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | WDR5 168/4885KMT2A 9/4885RBBP5 178/4885 |
| US-20120071418-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | WDR5 163/4885KMT2A 15/4885RBBP5 178/4885 |
| US-20140275081-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | EZH2, DOT1L, PRDM7 | WDR5 167/4885KMT2A 14/4885RBBP5 247/4885 |
| US-20130040906-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | WDR5 167/4885KMT2A 14/4885RBBP5 247/4885 |
| US-20150141362-A1 | Inhibitors of Human EZH2, and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | WDR5 167/4885KMT2A 14/4885RBBP5 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.